Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Core Viewpoint - Akari Therapeutics has announced the issuance of a new patent in India for its innovative immuno-oncology payload, PH1, which is designed to inhibit RNA splicing and enhance cancer treatment options as cancer rates rise in the region [1][3]. Company Overview - Akari Therapeutics is focused on developing novel antibody drug conjugates (ADCs) for cancer treatment, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [6]. - The company has developed PH1, a spliceosome inhibitor that disrupts RNA splicing, leading to cancer cell death and immune system activation [6]. Patent Details - The newly issued Patent No. 562,919 covers the company's PH1 payload, proprietary linkers, and ADC technology applicable to various cancer targets [2][4]. - This patent strengthens Akari's global intellectual property portfolio and provides additional protection for its manufacturing activities related to PH1 [3]. Market Context - India is identified as a key market for Akari, with cancer cases projected to rise to 2.08 million by 2040, highlighting the increasing need for innovative cancer therapies [1][3]. - The issuance of the patent is seen as a strategic move to capitalize on the growing demand for cancer treatments in India [3]. Research and Development - Akari is advancing a pipeline of potentially first-in-class ADC candidates that have demonstrated significant tumor-killing activity in preclinical models [5]. - The company aims to leverage its innovative payload platform to create multiple ADC molecules targeting a range of cancer types [5].